Gospodinova, Katerina O.
Olsen, Ditte
Kaas, Mathias
Anderson, Susan M.
Phillips, Jonathan
Walker, Rosie M.
Bermingham, Mairead L.
Payne, Abigail L.
Giannopoulos, Panagiotis
Pandya, Divya
Spires-Jones, Tara L.
Abbott, Catherine M.
Porteous, David J.
Glerup, Simon
Evans, Kathryn L. http://orcid.org/0000-0002-7884-5877
Funding for this research was provided by:
Alzheimer’s Research UK (ARUK-NC2019-SCO)
Article History
Received: 16 April 2021
Accepted: 29 October 2021
First Online: 6 November 2021
Declarations
:
: Although not related to the present study, SG is a shareholder of Muna Therapeutics and Teitur Trophics, both involved in developing therapies directed at SorCS2. The remaining authors declare that they have no competing interests.
: All experiments were approved by the Danish Animal Experiments Inspectorate under the Ministry of Justice (Permits 2011/561-119, 2016-15-0201-01127 and 2017-15-0201-01192) and carried out according to the ARRIVE guidelines.
: Not applicable.
: Not applicable.